Patients Treated in Real Life With VEnetoclax for WAldenström Macroglobulinemia

P

Poitiers University Hospital

Status

Enrolling

Conditions

Waldenstrom's Macroglobulinaemia Refractory

Treatments

Drug: Venetoclax

Study type

Observational

Funder types

Other

Identifiers

NCT06200220
WAVE

Details and patient eligibility

About

Waldenström macroglobulinemia (WM) is an incurable disease. BCL2 antagonist, an important anti-apoptosys molecule, is already approved for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia. Recently, a clinical trial including 32 patients with WM treated with Venetoclax showed an overall response rates of 84% and a major response rate of 81%. However, there is no in real life data, in the french population, of the efficiency of Venetoclax in WM. The aim of our multicentric retrospective study is to evaluate the efficiency and tolerance of Venetoclax in WM.

Enrollment

45 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  • Waldenstrom's macroglobulinemia
  • Treatment with Venetoclax
  • Non opposition

Exclusion Criteria: none

Trial contacts and locations

1

Loading...

Central trial contact

Mathilde Vonfeld, Intern; cécile tomowiak, Dr

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems